ArticleAsia Pacific allergy2025
Overcoming anaphylactic severe cow's milk allergy with slow and low-dose oral immunotherapy: A 10-year path to tolerance.
Article in Asia Pacific allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cow's milk allergy (CMA) is a common pediatric food allergy that can cause significant nutritional and quality-of-life challenges. Severe cases, characterized by high milk-specific IgE levels and a history of anaphylaxis, rarely develop natural tolerance. Oral immunotherapy (OIT) is generally avoided in such high-risk patients due to the risk of serious allergic reactions, leaving strict avoidance as the standard treatment. However, prolonged avoidance may delay tolerance acquisition and increase psychosocial burden. We report a female patient with severe CMA and multiple food allergies who underwent a carefully tailored, ultra-low-dose OIT over 10 years. At treatment initiation, her milk-specific IgE was >100 kUA/L, and an oral challenge with 1.1 mL of milk induced anaphylaxis. The OIT protocol started with a dose well below her reaction threshold and increased gradually, resulting in no serious adverse events. Over time, she achieved tolerance to 200 mL of pure milk and resumed unrestricted consumption of milk and other previously avoided foods such as egg and wheat. This is the first report of successful long-term ultra-low-dose OIT in a highly sensitized child with severe CMA, showing that slow, cautious escalation can safely induce unrestricted intake even in patients previously deemed unsuitable for OIT. Given the limitations of biologics and emergency care availability worldwide, this low-risk, home-based protocol using locally available foods offers a feasible and affordable approach for managing severe food allergies globally. Such individualized, sustained OIT may improve long-term outcomes and quality of life for children with severe food allergies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.